Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  ISIS Pharmaceuticals, Inc.    ISIS   US4643301090

Delayed Quote. Delayed Nasdaq - 12/19 04:00:06 pm
65.09 USD   +9.30%
1d ago ISIS PHARMACEUT : IWM, HEZU: Big ETF Inflows
4d ago ISIS PHARMACEUT : Initiates Phase 1/2 Study of ISIS-DMPK Rx in Patie..
12/11 ISIS PHARMACEUT : IWM, QAT: Big ETF Inflows
 SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
12/15/2014 12/16/2014 12/17/2014 12/18/2014 12/19/2014 Date
56.93(c) 54.94(c) 57.48(c) 59.55(c) 65.09(c) Last
4 410 587 4 136 662 2 623 190 2 147 533 9 637 875 Volume
-8.65% -3.50% +4.62% +3.60% +9.30% Change
More quotes
Company
Isis Pharmaceuticals, Inc. engages in the development and commercialization of drugs to treat various health conditions, including inflammatory, viral, metabolic and cardiovascular and dermatological diseases and cancer.The company operates in two segments: Drug Discovery & Development and... 
Sector
Biotechnology & Medical Research
Calendar
01/12 | 05:30pmPresentation
More about the company
Surperformance© ratings of ISIS Pharmaceuticals, Inc.
Trading Rating : Investor Rating :
More Ratings
Chart ISIS PHARMACEUTICALS, INC.
Duration : Period :
ISIS Pharmaceuticals, Inc. Technical Analysis Chart | ISIS | US4643301090 | 4-Traders
Full-screen chart
Financials ($)
Sales 2014 196 M
EBIT 2014 -58,0 M
Net income 2014 -69,5 M
Debt 2014 431 M
Yield 2014 -
Sales 2015 177 M
EBIT 2015 -112 M
Net income 2015 -137 M
Debt 2015 389 M
Yield 2015 -
PER 2014 -
PER 2015
EV / Sales 2014 41,4x
EV / Sales 2015 45,7x
Capitalization 7 690 M
More Financials
Latest news on ISIS PHARMACEUTICALS, INC.
1d ago ISIS PHARMACEUTICALS : IWM, HEZU: Big ETF Inflows
3d ago ISIS PHARMACEUTICALS : Reports Positive Phase 2 Data for ISIS-FXI Rx for the Pre..
4d ago ISIS PHARMACEUTICALS : Initiates Phase 1/2 Study of ISIS-DMPK Rx in Patients Wit..
5d ago ISIS PHARMACEUTICALS : Assigned Patent
12/11 ISIS PHARMACEUTICALS : IWM, QAT: Big ETF Inflows
12/11 ISIS PHARMACEUTICALS : -APOCIII Rx Phase 2 Study in Patients With Familial Chylo..
12/10 ISIS PHARMACEUTICALS : Releases Final Data from Phase 2 Study
12/08 ISIS PHARMACEUTICALS : Assigned Patent
More news
Sector news
1d ago ISIS PHARMACEUTICALS : IWM, HEZU: Big ETF Inflows
1d ago PUMA BIOTECHNOLOGY : SHAREHOLDER ALERT: Investigation on Behalf of Investors of ..
1d ago ALNYLAM PHARMACEUTICALS : Announces Planned Departure of Chief Business Officer,..
More sector news
4-Traders Strategies on ISIS PHARMACEUTICALS, INC. 
08/14A resistance as obstacle
More Strategies


Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF